CA
NZ
UK
AU
IND
US
Operating expenses rose 43% to USD 149.7 million. Compensation and benefits jumped 74% to USD 43.3 million, including a USD 14.8 million rise in stock-based compensation,Advertisingand activation rose 48% to USD 28.0 million and theCreditloss provision rose 22% to USD 36.5 million in line …
Key HighlightsAppLovin (NASDAQ:APP) traded 32.02% higher at USD 358.76 after third-quarterRevenueof USD 2,184.8 million andNet Incomeof USD 1,438.9 million.Veracyte, Inc. (NASDAQ:VCYT) fell 54.9% to USD 23.69 after lowering 2026 testing revenue guidance to USD 571 million to USD 573 million.Sezzle Inc. (NASDAQ:SEZL) rose 19.75% …
Loss from operations widened to USD 24.5 million from USD 21.3 million. The company received an unfavorableJuryverdict in litigation involving Intrepid Automation and booked a USD 12.5 million accrual in selling, general and administrative expense, which rose 33.5% to USD 46.4 million. It plans …
The company is a US natural gas and oil producer that grows by buying mature wells and hedging output. Production climbed 5% on the Canvas and Sheridan acquisitions and non-operated development, partly offset by the Barnett sale. Realized price including hedge settlements was USD …
ClearanceJobs revenue rose USD 2.6 million, which the filing attributes toDemandfor cleared professionals, product releases and the Point Solutions Group acquisition, completed on February 27, 2026 for an aggregate USD 5.4 million. Dice revenue fell USD 2.5 million as macroeconomic conditions lowered renewals among …
Key HighlightsGAAPDiluted Earnings per Sharewere USD 0.28 against USD 0.74 a year earlier, a fall of 62.2%, onNet Incomeof USD 13.0 million versus USD 33.7 million.Comparable adjusted diluted earnings per share rose 1.9% to USD 1.06 from USD 1.04, while adjusted EPS before removingBusinessexits …
The R&D increase of USD 24.1 million came from preclinical and clinical activity of USD 7.5 million,Manufacturingand control work of USD 7.5 million, personnel of USD 4.7 million and a USD 2.3 millionWarrantobligation tied to Paramora, a Paragon affiliate. Of the quarter's R&D, USD …
The Phase 3 EMERGE trial in generalized myasthenia gravis began in June 2026, with top-line results expected in the second half of 2028. The Phase 3 CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy reported a 75% response rate in an interim analysis of the …
Friedreich ataxia spending was USD 4.7 million in the quarter, while spending on the eye disease program fell to USD 0.5 million from USD 1.6 million. In May 2026 the company reported four-week data from its Phase 1/2 RESTORE-FA trial of DT-216P2, with a …
Key HighlightsNet sales for the quarter ended September 30, 2026 rose 12% to USD 9.7 million from USD 8.7 million, led by Quell Fibromyalgia and prescription gammaCore sold to the Veterans Affairs channel.Net loss narrowed to USD 1.3 million, or USD 0.13 per share, …
Please wait processing your request...